In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed.
Pulmonary function tests help a doctor to diagnose respiratory diseases and disorders such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema, and mechanical injury by measuring the degree of lung impairment.
It is usually associated with cancer, chronic obstructive pulmonary disease (COPD), or another chronic disease that progresses very slowly.
Short-acting ß2 agonists should be used as the initial treatment for COPD patients to relieve breathlessness.
Early identification is a priority if the debilitating, disabling, life shortening and expensive consequences of severe COPD are to be avoided.
